SGLT2阻害薬
参考資料

1 2 3  Shubrook, Jay; Baradar-Bokaie, Babak; Adkins, Sarah (2015). “Empagliflozin in the treatment of type 2 diabetes: Evidence to date”. Drug Design, Development and Therapy 9:  5793–803. doi:10.2147/DDDT.S69926. PMC 4634822. PMID 26586935. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4634822/.
↑  Usman, Muhammad Shariq; Siddiqi, Tariq Jamal; Memon, Muhammad Mustafa; Khan, Muhammad Shahzeb; Rawasia, Wasiq Faraz; Talha Ayub, Muhammad; Sreenivasan, Jayakumar; Golzar, Yasmeen (2018). “Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis”. European Journal of Preventive Cardiology 25 (5):  495–502. doi:10.1177/2047487318755531. PMID 29372664.
1 2 3  “Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence”. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 13:  161–174. (2020). doi:10.2147/DMSO.S233538. PMC 6982447. PMID 32021362. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6982447/.
↑  Scheen, André J. (2014). “Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus”. Drugs 75 (1):  33–59. doi:10.1007/s40265-014-0337-y. PMID 25488697.
↑  Haas, B.; Eckstein, N.; Pfeifer, V.; Mayer, P.; Hass, M D S. (2014). “Efficacy, safety and regulatory status of SGLT2 inhibitors: Focus on canagliflozin”. Nutrition & Diabetes 4 (11):  e143. doi:10.1038/nutd.2014.40. PMC 4259905. PMID 25365416. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4259905/.
1 2  Clar, Christine; Gill, James Alexander; Court, Rachel; Waugh, Norman (2012). “Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes”. BMJ Open 2 (5):  e001007. doi:10.1136/bmjopen-2012-001007. PMC 3488745. PMID 23087012. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488745/.
↑  Nauck, Michael (2014). “Update on developments with SGLT2 inhibitors in the management of type 2 diabetes”. Drug Design, Development and Therapy 8:  1335–80. doi:10.2147/DDDT.S50773. PMC 4166348. PMID 25246775. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4166348/.
↑  Zheng, Sean L.; Roddick, Alistair J.; Aghar-Jaffar, Rochan; Shun-Shin, Matthew J.; Francis, Darrel; Oliver, Nick; Meeran, Karim (2018). “Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors with All-Cause Mortality in Patients with Type 2 Diabetes”. JAMA 319 (15):  1580–1591. doi:10.1001/jama.2018.3024. PMC 5933330. PMID 29677303. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5933330/.
↑  Nashawi, Mouhamed; Sheikh, Omar; Battisha, Ayman; Ghali, Abdullah; Chilton, Robert (May 2021). “Neural tone and cardio-renal outcomes in patients with type 2 diabetes mellitus: a review of the literature with a focus on SGLT2 inhibitors”. Heart Failure Reviews 26 (3):  643–652. doi:10.1007/s10741-020-10046-w. ISSN 1573-7322. PMID 33169337. https://pubmed.ncbi.nlm.nih.gov/33169337/.
↑  “Sodium-Glucose Cotransporter-2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis”. Circulation. 149 (23):  1789-1801.. (Jun 2024). doi:10.1161/CIRCULATIONAHA.124.069568.. PMC PMC11149938. PMID 38583093. https://www.ncbi.nlm.nih.gov/pmc/articles/PMCPMC11149938/.
↑  Rami Aldafas, Tomas Crabtree, Mohammed Alkharaiji, Yana Vinogradova, Iskandar Idris "Sodium-glucose cotransporter-2 inhibitors (SGLT2) in frail or older people with type 2 diabetes and heart failure: a systematic review and meta-analysis" Age Ageing. 2024 Jan 2;53(1):afad254. doi: 10.1093/ageing/afad254.
↑  “Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis”. Lancet Diabetes Endocrinol. 12 (7):  447-461.. (July 2024). doi:10.1016/S2213-8587(24)00102-5.. PMID 38768620.
1 2  Hsia, Daniel S.; Grove, Owen; Cefalu, William T. (2016). “An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus”. Current Opinion in Endocrinology, Diabetes and Obesity 24 (1):  73–79. doi:10.1097/MED.0000000000000311. PMC 6028052. PMID 27898586. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6028052/.
↑  Isaacs, Michelle; Tonks, Katherine T.; Greenfield, Jerry R. (2017). “Euglycaemic diabetic ketoacidosis in patients using sodium-glucose co-transporter 2 inhibitors”. Internal Medicine Journal 47 (6):  701–704. doi:10.1111/imj.13442. PMID 28580740.
↑  Milder, D. A.; Milder, T. Y.; Kam, P. C. A. (August 2018). “Sodium-glucose co-transporter type-2 inhibitors: pharmacology and peri-operative considerations” (英語). Anaesthesia 73 (8):  1008–1018. doi:10.1111/anae.14251. PMID 29529345.
↑  Khouri, Charles; Cracowski, Jean-Luc; Roustit, Matthieu (2018). “SGLT-2 inhibitors and the risk of lower-limb amputation: Is this a class effect?”. Diabetes, Obesity and Metabolism 20 (6):  1531–1534. doi:10.1111/dom.13255. PMID 29430814.
↑  “SGLT2 inhibitors: information on potential risk of toe amputation to be included in prescribing information”. European Medicines Agency (4 May 2017). 2022年1月25日閲覧。
↑  “FDA warns about rare occurrences of a serious infection of the genital area with SGLT2 inhibitors for diabetes” (英語). www.fda.gov.   Center for Drug Evaluation and Research. p. Drug Safety and Availability (7 September 2018). 16 April 2019閲覧。
↑  Bardia, Amit; Wai, Mabel; Fontes, Manuel L. (February 2019). “Sodium-glucose cotransporter-2 inhibitors: an overview and perioperative implications” (英語). Current Opinion in Anesthesiology 32 (1):  80–85. doi:10.1097/ACO.0000000000000674. PMID 30531609. http://insights.ovid.com/crossref?an=00001503-201902000-00014.
1 2  “FDA revises labels of SGLT2 inhibitors for diabetes to include warning”. U.S. Food and Drug Administration (19 March 2020). 6 June 2020閲覧。  この記述には、アメリカ合衆国内でパブリックドメインとなっている記述を含む。
↑  “「SGLT2阻害薬の適正使用に関する委員会」から｜一般社団法人日本糖尿病学会”. www.jds.or.jp. 2023年2月28日閲覧。
↑   BNF 73. Tavistock Square, London: BMJ Group. (March–September 2017)
↑  Scheen, André J. (2014). “Drug–Drug Interactions with Sodium-Glucose Cotransporters Type 2 (SGLT2) Inhibitors, New Oral Glucose-Lowering Agents for the Management of Type 2 Diabetes Mellitus”. Clinical Pharmacokinetics 53 (4):  295–304. doi:10.1007/s40262-013-0128-8. hdl:2268/164207. PMID 24420910. http://orbi.ulg.ac.be/handle/2268/164207.
1 2  Bhartia, Mithun; Tahrani, Abd A.; Barnett, Anthony H. (2011). “SGLT-2 Inhibitors in Development for Type 2 Diabetes Treatment”. The Review of Diabetic Studies 8 (3):  348–354. doi:10.1900/RDS.2011.8.348. PMC 3280669. PMID 22262072. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3280669/.
↑  Yang, Li; Li, Haiyan; Li, Hongmei; Bui, Anh; Chang, Ming; Liu, Xiaoni; Kasichayanula, Sreeneeranj; Griffen, Steven C. et al. (2013). “Pharmacokinetic and Pharmacodynamic Properties of Single- and Multiple-Dose of Dapagliflozin, a Selective Inhibitor of SGLT2, in Healthy Chinese Subjects”. Clinical Therapeutics 35 (8):  1211–1222.e2. doi:10.1016/J.Clinthera.2013.06.017. PMID 23910664.
↑  Chao, E. C. (2014). “SGLT-2 Inhibitors: A New Mechanism for Glycemic Control”. Clinical Diabetes 32 (1):  4–11. doi:10.2337/diaclin.32.1.4. PMC 4521423. PMID 26246672. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4521423/.
1 2 3  Anderson, Sarah L.; Marrs, Joel C. (2012). “Dapagliflozin for the Treatment of Type 2 Diabetes”. Annals of Pharmacotherapy 46 (4):  590–598. doi:10.1345/aph.1Q538. PMID 22433611.
1 2 3  Li, An-Rong; Zhang, Jian; Greenberg, Joanne; Lee, Taeweon; Liu, Jiwen (2011). “Discovery of non-glucoside SGLT2 inhibitors”. Bioorganic & Medicinal Chemistry Letters 21 (8):  2472–2475. doi:10.1016/j.bmcl.2011.02.056. PMID 21398124.
↑  Hummel, Charles S.; Lu, Chuan; Liu, Jie; Ghezzi, Chiari; Hirayama, Bruce A.; Loo, Donald D. F.; Kepe, Vladimir; Barrio, Jorge R. et al. (2012). “Structural selectivity of human SGLT inhibitors”. American Journal of Physiology. Cell Physiology 302 (2):  C373–C382. doi:10.1152/ajpcell.00328.2011. PMC 3328840. PMID 21940664. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3328840/.
1 2  Plosker, Greg L. (2012). “Dapagliflozin”. Drugs 72 (17):  2289–2312. doi:10.2165/11209910-000000000-00000. PMID 23170914.
↑  “Jardiance”. drugs.com.   Drugs.com. 31 October 2014閲覧。
↑  “Farxiga”. drugs.com.   Drugs.com. 31 October 2014閲覧。
↑  “Invokana”. drugs.com.   Drugs.com. 31 October 2014閲覧。
↑  Madaan, Tushar; Akhtar, Mohd.; Najmi, Abul Kalam (2016). “Sodium glucose Co Transporter 2 (SGLT2) inhibitors: Current status and future perspective”. European Journal of Pharmaceutical Sciences 93:  244–252. doi:10.1016/j.ejps.2016.08.025. PMID 27531551.
↑  LARSON, GERALD L. (March–April 2015). “The synthesis of gliflozins”. Chimica Oggi - Chemistry Today 33 (2):  37–40. http://www.teknoscienze.com/getpdf.php?filename=Contents%2FRiviste%2FPDF%2FCO2_Oligos-Peptides_2015_RGB.pdf&beginpage=39&endpage=42&filetitle=The%20synthesis%20of%20gliflozins.
↑  Chen, Zeng-Hao; Wang, Ruo-Wen; Qing, Feng-Ling (2012). “Synthesis and biological evaluation of SGLT2 inhibitors: Gem-difluoromethylenated Dapagliflozin analogs”. Tetrahedron Letters 53 (17):  2171–2176. doi:10.1016/j.tetlet.2012.02.062.
↑  Ng, Wai-Lung; Li, Ho-Chuen; Lau, Kit-Man; Chan, Anthony K. N.; Lau, Clara Bik-San; Shing, Tony K. M. (17 July 2017). “Concise and Stereodivergent Synthesis of Carbasugars Reveals Unexpected Structure-Activity Relationship (SAR) of SGLT2 Inhibition” (英語). Scientific Reports 7 (1):  5581. Bibcode: 2017NatSR...7.5581N. doi:10.1038/s41598-017-05895-9. ISSN 2045-2322. PMC 5514135. PMID 28717146. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514135/.
↑  Ng, Wai-Lung; Li, Ho-Chuen; Lau, Kit-Man; Chan, Anthony K. N.; Lau, Clara Bik-San; Shing, Tony K. M. (2017). “Concise and Stereodivergent Synthesis of Carbasugars Reveals Unexpected Structure-Activity Relationship (SAR) of SGLT2 Inhibition”. Scientific Reports 7 (1):  5581. Bibcode: 2017NatSR...7.5581N. doi:10.1038/s41598-017-05895-9. PMC 5514135. PMID 28717146. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514135/.
↑  “7.5: Electron Affinities”. Chemistry LibreTexts (18 November 2014). 30 September 2018閲覧。
↑  Song, Kwang-Seop; Lee, Suk Ho; Kim, Min Ju; Seo, Hee Jeong; Lee, Junwon; Lee, Sung-Han; Jung, Myung Eun; Son, Eun-Jung et al. (2010). “Synthesis and SAR of Thiazolylmethylphenyl Glucoside as Novel C-Aryl Glucoside SGLT2 Inhibitors”. ACS Medicinal Chemistry Letters 2 (2):  182–187. doi:10.1021/ml100256c. PMC 4018110. PMID 24900297. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4018110/.
↑  Madaan, Tushar; Husain, Ibraheem; Akhtar, Mohamad; Najmi, Abul Kalam (2018). “Exploring novel pharmacotherapeutic applications and repurposing potential of sodium glucose Co Transporter 2 inhibitors”. Clinical and Experimental Pharmacology and Physiology 45 (9):  897–907. doi:10.1111/1440-1681.12963. PMID 29751356.
↑  “日本初のSGLT2阻害薬「スーグラ錠」承認取得”. 糖尿病リソースガイド. 2022年1月25日閲覧。
↑  Poole, Raewyn M.; Dungo, Rosselle T. (26 March 2014). “Ipragliflozin: First Global Approval”. Drugs 74 (5):  611–617. doi:10.1007/s40265-014-0204-x. PMID 24668021.
↑  “Forxiga EPAR”. European Medicines Agency (EMA). 17 February 2020閲覧。
↑  “Drug Approval Package: Farxiga (dapagliflozin) Tablets NDA #202293”. U.S. Food and Drug Administration (FDA) (24 December 1999). 5 May 2020閲覧。
↑  “2型糖尿病治療薬「フォシーガ®錠5㎎、10㎎」 製造販売承認取得のお知らせ”. www.astrazeneca.co.jp. 2022年1月25日閲覧。
↑  Poole, Raewyn M.; Prossler, Jennifer E. (2014). “Tofogliflozin: First Global Approval”. Drugs 74 (8):  939–944. doi:10.1007/s40265-014-0229-1. PMID 24848755.
↑  “選択的 SGLT2 阻害剤「デベルザ®錠 20mg、アプルウェイ®錠 20mg」 「CSG452（一般名：トホグリフロジン水和物）」の 国内での製造販売承認取得について”. 2022年1月25日閲覧。
↑  Markham, Anthony; Elkinson, Shelley (2014). “Luseogliflozin: First Global Approval”. Drugs 74 (8):  945–950. doi:10.1007/s40265-014-0230-8. PMID 24848756.
↑  日経メディカル. “SGLT-2阻害薬、3成分が同時承認で計4成分へ”. 日経メディカル. 2022年1月25日閲覧。
↑  “Drug Approval Package: Invokana (canagliflozin) Tablets NDA #204042”. U.S. Food and Drug Administration (FDA) (24 December 1999). 5 May 2020閲覧。
↑  “Invokana EPAR”. European Medicines Agency (EMA). 1 October 2018閲覧。
↑  “２型糖尿病治療剤「カナグル錠100mg」の国内製造販売承認取得のお知らせ” (2014年7月4日). 2014年10月31日閲覧。
↑  “FDA approves Jardiance (empagliflozin) tablets for adults with type 2 diabetes”. Boehringer Ingelheim / Eli Lilly and Company. (1 August 2014).  オリジナルの5 November 2014時点におけるアーカイブ。. https://web.archive.org/web/20141105201008/http://us.boehringer-ingelheim.com/news_events/press_releases/press_release_archive/2014/08-01-14-fda-approves-jardiance-empagliflozin-tablets-reduce-blood-sugar-levels-adults-type-2-diabetes.html 5 November 2014閲覧。
↑  “2型糖尿病治療薬/選択的SGLT2阻害剤「ジャディアンス錠」製造販売承認取得のお知らせ” (2014年12月26日). 2015年2月25日閲覧。
↑  “FDA Advisory Committee recommends approval of Jardiance (empagliflozin) for cardiovascular indication in 12-11 vote”. (28 June 2016). https://finance.yahoo.com/news/fda-advisory-committee-recommends-approval-222200556.html;_ylt=A0LEVrhllatXlP8AlncnnIlQ;_ylu=X3oDMTByOHZyb21tBGNvbG8DYmYxBHBvcwMxBHZ0aWQDBHNlYwNzcg-- 10 August 2016閲覧。
↑  臨床試験番号 NCT02531035 研究名 "A Phase 3 Study to Evaluate the Safety of Sotagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycemic Control With Insulin Therapy Alone (inTandem3)" - ClinicalTrials.gov
↑  “Sotagliflozin as an Adjunct to Insulin for Type 1 Diabetes - FDA”. 2022年1月25日閲覧。
↑  Sanofi (17 January 2019). “Sanofi: FDA advisory committee votes on Zynquista(TM) (sotagliflozin) as treatment for adults with type 1 diabetes”. GlobeNewswire News Room. 2022年1月25日閲覧。
ネフロンにおけるグルコースの再吸収
フロリジン
ダパグリフロジン
エンパグリフロジン
カナグリフロジン